Supporting people to get tested and be free of hep C
Gilead Sciences UK Ltd works in partnership with NHS England, drug and alcohol services, prison services, the Hepatitis C Trust, regional clinical liver HCV Operational Delivery Networks (ODNs), commissioners and third-sector organisations to help us to achieve HCV elimination before the World Health Organisation goal of 2030.1
Click below to find out how we work with:
GILEAD HCV DTS PROVIDER FORUM
The Gilead HCV Drug Treatment Services Provider Forum is united in our shared commitment to eliminate Hepatitis C in England. Recognising the urgency of this public health challenge to achieve this goal ahead of the World Health Organisation target of 2030,1 we pledge to work collaboratively, leveraging our collective expertise and resources.
Our principles
The Gilead HCV DTS Provider Forum is dedicated to eliminating hepatitis C for drug and alcohol service users in England by fostering collaboration and innovation to create a healthier, stigma-free community.
DTS HCV Provider Forum Podcast
Check out our podcast to learn more about how drug and alcohol service providers are working collaboratively with the NHS, the Hepatitis C Trust and Gilead Sciences to leverage collective expertise to achieve HCV elimination in England.
Our Mission
The HCV DTS provider Forum is united in our commitment to eliminate hepatitis C for drug and alcohol service users in England, driving change through collaboration and fostering a healthier, stigma free, community for our service users.
CLICK HERE TO VIEW LIST OF ELIMINATED SERVICES AND HUBS
NHS Addictions Provider Alliance (APA)
Aldershot ~
Andover ~
Aspire Bury
Basingstoke ~
Bath and N E Somerset, AWP
BDP Bristol
Bucks ~
Clean Slate
Fareham ~
Gosport ~
Hillingdon
Hounslow
Isle Of Wight ~
MerseyCare
Milton Keynes
Richmond *
Ringwood ~
Solihull
Stockport
Telford ~
Winchester ~
Change, Grow, Live (CGL)
Bham East (Hub)
Camden
C. Lancs
CGL Cambridgeshire
Crewe
E. Lancs
G. Yarmouth (Hub)
Halton
Havering
Knowsley
N. Lancs
Newark/Bassetlaw (Hub)
Rotherham
Sefton
St Helens
Stockton
Tameside
Warrington
Waltham Forest
Wirral
Wisbech (Hub)
Worthing (Hub)
Turning Point (TP)
Hereford
Oxford
Slough
Via
Brent
Harrow
Merton
West Berkshire
With You (WY)
Boston (Hub)
Darlington
Liverpool
North Somerset
Scunthorpe
Shropshire
Waythrough (WAY)
Barnsley
Calderdale
Leeds Irford
Leeds IrfordLewisham
S Tyneside
South Cumbria
~ NHS Inclusion Services
* NHS SLAM Service
DRUG AND ALCOHOL SERVICES
In the UK, injecting drug use remains one of the primary routes of hepatitis C transmission.3 To address this, Gilead Sciences Inc. has partnered with most drug and alcohol service providers across England as part of NHS England’s strategic procurement initiative for hepatitis C. This collaboration provides critical support and resources to help each service achieve elimination, targeting completion ahead of the World Health Organisation’s 2030 goal.1
Gilead's non-promotional hep c patient finding team works with local drug and alcohol services, in partnership with Operational Delivery Networks and the Hepatitis C Trust to increase screening and linkage to care through training, support and pathway optimisation.
More than 10,000 people in drug services have been treated for HCV, and 63 drug services have declared micro-elimination as of March 2025
COMMISSIONERS AND SERVICE LEADERS
The Gilead Regional Market Access team collaborates closely with National and Regional commissioners, Local Authority Drug and Alcohol substance misuse commissioners, OHID, UKHSA, and Directors of Public Health, as well as other key decision-makers across the UK. Our roles and interactions are tailored to the needs and experience levels of the commissioners we engage with, ensuring that our support is relevant, effective, and responsive.
Our team provides essential education on the impact of Hepatitis C on both individuals and communities. This includes highlighting the healthcare costs associated with untreated Hepatitis C and the significant improvements in population health that can be achieved through effective intervention. By fostering informed discussions, we help services understand how optimising Hepatitis C testing and treatment can create long-term benefits for patients and communities alike.
PRISON SERVICES
Gilead is actively partnering with several prison service providers to support patient identification and linkage to hepatitis C care. With a high prevalence of HCV in prison populations,4 targeted initiatives to improve testing and treatment are essential to achieving elimination in these settings.
Our collaboration with prison services
As part of NHS England’s strategic procurement for hepatitis C, Gilead Sciences Inc. has collaborated with prison service providers Practice Plus Group, Spectrum, and Oxleas to enhance reception testing and establish a new model of rapid testing and treatment in prison settings. This enhanced testing protocol has improved HCV screening among new arrivals across 47 prisons in England, offering a viable approach for achieving HCV micro-elimination within prison systems. The protocol is adaptable to the specific needs of prisons worldwide, helping improve HCV screening and treatment outcomes. For more details on the reception testing protocols, please view the recent publication in the Journal of Hepatology here.5
Our development of high-intensity test-and-treat (HITT) models has led to the elimination of hepatitis C in 40 prisons, with over 4,000 individuals treated in Gilead-partnered prisons since 2019. This progress is the result of strong partnerships with established prison elimination providers and the rapid successes achieved through collaborations with new partners, building on years of skills development and insights. For more information on HITT models, please contact Louise Missen.
OPERATIONAL DELIVERY NETWORKS
Operational Delivery Networks (ODNs) play a vital role in partnership with NHS England and local services to identify and treat individuals living with hepatitis C. ODNs are instrumental in providing treatment services that address the needs of people living with HCV.
By working within communities, they enable streamlined and effective care, helping to reduce barriers to treatment and ensuring that vulnerable populations receive the support they need. ODNs work tirelessly to reduce hepatitis C related mortality, increasing health equity and bringing England closer to achieving hepatitis C elimination.6
Gilead partners closely with ODNs to strengthen their connections with local services, to increase testing and treatment, as part of our ambition to achieve elimination in England before 2030.
Click here to find your ODNs Patient Access to Care Lead
BEYOND ENGLAND
At Gilead, we are working to achieve elimination of Hepatitis C across the UK and Ireland by partnering with health service providers, healthcare professionals, drug treatment services, prisons and patient organisations, to reach the diverse and often marginalised communities we serve.
This approach has focused on optimising current testing, diagnosis and treatment pathways within local services, prisons and wider across health boards utilising service and pathway mapping, training and education events as well as providing access to awareness materials and online downloadable resources to raise awareness of risk factors and promote testing.
Successful joint working has supported implementation of rapid point of care testing (Step-C Free) and the creation of community based, peer -led outreach (Peer Based Hepatitis C Patient Finding in Glasgow).
